Professor of Translational OncoProteomics, Dept. Medical Oncology, and Head of the OncoProteomics Laboratory and Director of the Proteomics Core, Amsterdam University Medical Center
Biography
Connie Jimenez is a biologist and proteome researcher who pioneered single cell neuropeptide profiling by mass spectrometry in the 1990s during her Ph.D. studies at the Vrije Universiteit in Amsterdam. She then performed post-doctoral neuroproteomics research at the University of California-San Francisco and Vrije Universiteit.
In 2006, Dr. Jimenez founded the OncoProteomics Laboratory at Cancer Center Amsterdam to employ the power of mass spectrometry-based proteomics to study cancer (www.oncoproteomics.nl). Her lab's mission is to apply innovative mass spectrometry-based phosphoproteomics and data analysis to improve early diagnosis and treatment of cancer and neurodegenerative diseases. Label-free proteomics and dedicated data analysis strategies are employed to investigate extracellular proteins in in vitro and in vivo proximal fluids (urine, CSF, stool) to develop non-invasive biomarker applications, and intracellular phosphoproteins to enable patient stratification and response prediction. These approaches have been successfully applied in multiple collaborative projects in various cancers including colorectal, breast, lung, prostate, and pancreatic cancer, leukemia, and neurodegenerative diseases.
Dr. Jimenez has authored over 140 peer-reviewed articles, 11 book chapters, and 8 articles in popular science and clinical journals. She is active in several international proteomics networks: founder and member of the Steering Committee of the Netherlands Proteomics Platform, general council member of the European Proteomics Association, co-chair of the Cancer Initiative of the Human Proteome Organization. Dr. Jimenez serves on the editorial boards of Journal of Proteomics, Molecular and Cellular Proteomics, Proteomics, and Clinical Proteomics.
In 2006, Dr. Jimenez founded the OncoProteomics Laboratory at Cancer Center Amsterdam to employ the power of mass spectrometry-based proteomics to study cancer (www.oncoproteomics.nl). Her lab's mission is to apply innovative mass spectrometry-based phosphoproteomics and data analysis to improve early diagnosis and treatment of cancer and neurodegenerative diseases. Label-free proteomics and dedicated data analysis strategies are employed to investigate extracellular proteins in in vitro and in vivo proximal fluids (urine, CSF, stool) to develop non-invasive biomarker applications, and intracellular phosphoproteins to enable patient stratification and response prediction. These approaches have been successfully applied in multiple collaborative projects in various cancers including colorectal, breast, lung, prostate, and pancreatic cancer, leukemia, and neurodegenerative diseases.
Dr. Jimenez has authored over 140 peer-reviewed articles, 11 book chapters, and 8 articles in popular science and clinical journals. She is active in several international proteomics networks: founder and member of the Steering Committee of the Netherlands Proteomics Platform, general council member of the European Proteomics Association, co-chair of the Cancer Initiative of the Human Proteome Organization. Dr. Jimenez serves on the editorial boards of Journal of Proteomics, Molecular and Cellular Proteomics, Proteomics, and Clinical Proteomics.